Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa

Clinical Nephrology

Volumn 66, Issue 6, 2006, Pages 464-467

  Izquierdo, M J ^a   Gomez Alamillo, C ^a   Ortiz, F ^a   Calabia, E R ^a   Ruiz, J C ^a   de Francisco, A L M ^a   Arias Rodriquez, M ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Acute renal failure; Chronic obstructive pulmonary disease; Inhaled tobramycin

Indexed keywords

AMINOGLYCOSIDE; BRONCHODILATING AGENT; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GENTAMICIN; GLUCOCORTICOID; OMEPRAZOLE; OXYGEN; SEROTONIN UPTAKE INHIBITOR; STEROID; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; AGED; ANAMNESIS; ARTICLE; BACTERIAL COLONIZATION; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; LABORATORY TEST; PHYSICAL EXAMINATION; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION;

EID: 33845456749     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66464     Document Type: Article

References (24)

1. Ahya VN, Doyle AM, Mendez JD, Lipson DA, Christie JD, Blumberg EA, Pochettino A, Nelson L, Bloom RD, Kotloff RH. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant. 2005; 24: 932-935
2. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003; 63: 2501-2520.
3. Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest. 2001; 120 (Suppl 3): 114S-117S.
4. Dennis JH, Pieron CA. Inhaled antibiotic therapy in evidence, what delivery device? J Cyst Fibros. 2002; 1 (Suppl 2): 209-214.
5. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother. 2005; 39: 39-44
6. Edson RS, Brey RH, McDonald TJ, Terrell CL, McCarthy JT, Thibert JM. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc. 2004; 79: 1185-1191.
7. Funck-Brentano C, Chatellier G, Alexandre JM. Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure. Br Heart J. 1986; 55: 596-598.
8. Garau J, Gomez L. Pseudomonas aeruginosa pneumonia. Curr Opin Infect Dis. 2003; 16: 135-143.
9. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002; 122: 219-226.
10. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW, AeroDose TOBI Study Group. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest. 2003; 123: 28-36.
11. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol. 2002; 34: 375-377.
12. Hricik DE, Dunn MJ. Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol. 1990; 1: 845-858.
13. Khaler DA, Schowengerdt KO, Fricker FJ, Mansfield M, Visner GA, Faro A. Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy. 2003; 23: 543-545.
14. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf. 2000; 22: 479-485.
15. Matzke GR, Halstenson CE, Keane WF. Hemodialysis elimination rates and clearance of gentamicin and tobramycin. Antimicrob Agents Chemother. 1984; 25: 128-130.
16. Moffet BS, Rosenstein BJ, Mogayzel PJ Jr. Ciprofloxacin-induced renal insufficiency in cystic fibrosis. J Cyst Fibros. 2003; 2: 152-154.
17. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, Weers JG. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003; 124: 360-366.
18. O'Riordan T, Faris M. Inhaled antimicrobial therapy. Respir Care Clin North Am. 1999; 5: 617-631.
19. O'Riordan TG. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir Care. 2000; 45: 836-845.
20. Ramsey BW, Pepe MS. Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999; 340: 23-30.
21. Rosenfeld M, Cohen M, Pharm B. Acrosolized antibiotics for bacterial lower airway infections: principles, efficacy and pitfalls. Clin Pulm Med. 1997; 4: 101-112.
22. Smith AL. Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation? Cyst Fibros. 2002; Suppl 2: 189-193.
23. Smith AL, Ramsey BW, Hedges DL et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989; 7: 265-271.
24. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Briemer DD. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 1997; 41: 184-187.